This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Eyebright Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 24, 2024. CI
Eyebright Medical Technology Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares. CI
Eyebright Medical Technology Co., Ltd. authorizes a Buyback Plan. CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Eyebright Medical Technology Co., Ltd.(XSSC:688050) added to S&P Global BMI Index CI
Eyebright Medical Technology Co., Ltd.(XSSC:688050) added to FTSE All-World Index CI
Eyebright Medical Technology Plans GDR Issue to Fund Projects, Boost Capital CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Eyebright Medical Technology's Phakic Intraocular Lens Pass Special Review MT
Eyebright Medical Technology Co., Ltd. agreed to acquire additional 14.1579% stake in Fujian Unicon Optical Co., Ltd from Hong Kong Unicon Optical Co. for CNY 70.1 million. CI
Certain A Shares of Eyebright Medical Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-JUL-2023. CI
Fujian Unicon Optical Co., Ltd announced that it expects to receive CNY 175 million in funding from Eyebright Medical Technology Co., Ltd. CI
IB Settlement Unit in Negotiations to Receive 100 Million Yuan Capital Injection from Eyebright Medical MT
Fujian Unicon Optical Co., Ltd announced that it expects to receive CNY 100 million in funding from Eyebright Medical Technology Co., Ltd. CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Eyebright Medical Technology Logs 35.3% Jump in 2022 Profit MT
Eyebright Medical Technology Gets Conditional Nod For Swiss IPO MT
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tianjin Zhengli Technology Co., Ltd. announced that it has received $15.7 million in funding from 3E Bioventures Capital, Eyebright Medical Technology Co., Ltd. and another investor CI
Eyebright Medical Technology Co., Ltd.(SHSE:688050) added to Shanghai Stock Exchange Health Care Sector Index CI
Chart Eyebright Medical Technology (Beijing) Co., Ltd.
More charts
Eyebright Medical Technology Beijing Co Ltd is a China-based company principally involved in the research, development, manufacturing and sales of ophthalmic medical devices. Its main products include ophthalmic surgery and optometry. Surgical products mainly include intraocular lens, capsular tension ring, intraocular lens implantation system, ophthalmic viscoelastic agent, various types of ophthalmic microsurgical instruments and ophthalmic scalpels, and optometry products include corneal orthopaedics (night-wear type), hard contact lens (daily-wear type) and tear test paper, among others. The Company conducts its businesses in domestic and overseas markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
141.5 CNY
Average target price
214.5 CNY
Spread / Average Target
+51.59%
Consensus
  1. Stock Market
  2. Equities
  3. 688050 Stock
  4. News Eyebright Medical Technology (Beijing) Co., Ltd.
  5. Eyebright Medical Technology Gets Conditional Nod For Swiss IPO